Chemotherapy in advanced ovarian cancer: four systematic meta-analyses of individual patient data from 37 randomized trials
1998

Chemotherapy for Advanced Ovarian Cancer

Sample size: 5667 publication Evidence: moderate

Author Information

Author(s): K Aabo, M Adams, P Adnitt, DS Alberts, A Athanazziou, V Barley, DR Bell, U Bianchi, G Bolis, MF Brady, HS Brodovsky, H Bruckner, M Buyse, R Canetta, V Chylak, CJ Cohen, N Colombo, PF Conte, D Crowther, JH Edmonson, C Gennatas, E Gilbey, M Gore, D Guthrie, SB Kaye, AH Laing, F Landoni, RC Leonard, C Lewis, PY Liu, C Mangioni, S Marsoni, H Meerpohl, GA Omura, MKB Parmar, J Pater, S Pecorelli, M Presti, W Sauerbrei, DV Skarlos, RV Smalley, HJ Solomon, LA Stewart, JFG Sturgeon, MHN Tattersall, JT Wharton, WW ten Bokkel Huinink, M Tomirotti, W Torri, C Trope, MM Turbow, JB Vermorken, MJ Webb, DW Wilbur, CJ Williams, E Wiltshaw, BY Yeap

Hypothesis

Does platinum-based chemotherapy provide better outcomes than non-platinum therapies in advanced ovarian cancer?

Conclusion

Platinum-based chemotherapy is more effective than non-platinum therapy, with no significant difference between cisplatin and carboplatin.

Supporting Evidence

  • The study included data from 37 randomized trials.
  • 5667 patients were analyzed for treatment outcomes.
  • Results indicated a trend favoring platinum combinations over single-agent platinum.
  • Cisplatin and carboplatin were found to be equally effective.
  • No significant evidence was found that one platinum drug was better than the other in specific patient subgroups.

Takeaway

Using platinum drugs helps women with advanced ovarian cancer live longer than using other types of chemotherapy.

Methodology

Systematic meta-analysis of individual patient data from 37 randomized controlled trials.

Potential Biases

Potential bias due to the inclusion of both published and unpublished trials.

Limitations

Many trials were small and results were sometimes inconclusive.

Participant Demographics

5667 patients from various trials, demographics not specified.

Statistical Information

P-Value

0.02

Confidence Interval

95% CI 1-8% benefit

Statistical Significance

p<0.05

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication